S&P 500   4,208.20 (-0.05%)
DOW   33,334.96 (+0.08%)
QQQ   324.21 (-0.53%)
AAPL   168.76 (-0.28%)
MSFT   287.13 (-0.70%)
META   177.45 (-0.50%)
GOOGL   118.99 (-0.59%)
AMZN   140.55 (-1.50%)
TSLA   858.99 (-2.73%)
NVDA   179.45 (-0.84%)
NIO   20.91 (+4.29%)
BABA   94.66 (+2.41%)
AMD   98.21 (-0.85%)
MU   62.41 (+1.64%)
T   18.06 (+0.28%)
CGC   3.16 (-3.95%)
GE   78.94 (+2.33%)
F   15.80 (+1.94%)
DIS   117.40 (+4.42%)
AMC   25.61 (+8.20%)
PYPL   99.05 (+0.14%)
PFE   48.26 (-3.38%)
NFLX   242.71 (-0.57%)
S&P 500   4,208.20 (-0.05%)
DOW   33,334.96 (+0.08%)
QQQ   324.21 (-0.53%)
AAPL   168.76 (-0.28%)
MSFT   287.13 (-0.70%)
META   177.45 (-0.50%)
GOOGL   118.99 (-0.59%)
AMZN   140.55 (-1.50%)
TSLA   858.99 (-2.73%)
NVDA   179.45 (-0.84%)
NIO   20.91 (+4.29%)
BABA   94.66 (+2.41%)
AMD   98.21 (-0.85%)
MU   62.41 (+1.64%)
T   18.06 (+0.28%)
CGC   3.16 (-3.95%)
GE   78.94 (+2.33%)
F   15.80 (+1.94%)
DIS   117.40 (+4.42%)
AMC   25.61 (+8.20%)
PYPL   99.05 (+0.14%)
PFE   48.26 (-3.38%)
NFLX   242.71 (-0.57%)
S&P 500   4,208.20 (-0.05%)
DOW   33,334.96 (+0.08%)
QQQ   324.21 (-0.53%)
AAPL   168.76 (-0.28%)
MSFT   287.13 (-0.70%)
META   177.45 (-0.50%)
GOOGL   118.99 (-0.59%)
AMZN   140.55 (-1.50%)
TSLA   858.99 (-2.73%)
NVDA   179.45 (-0.84%)
NIO   20.91 (+4.29%)
BABA   94.66 (+2.41%)
AMD   98.21 (-0.85%)
MU   62.41 (+1.64%)
T   18.06 (+0.28%)
CGC   3.16 (-3.95%)
GE   78.94 (+2.33%)
F   15.80 (+1.94%)
DIS   117.40 (+4.42%)
AMC   25.61 (+8.20%)
PYPL   99.05 (+0.14%)
PFE   48.26 (-3.38%)
NFLX   242.71 (-0.57%)
S&P 500   4,208.20 (-0.05%)
DOW   33,334.96 (+0.08%)
QQQ   324.21 (-0.53%)
AAPL   168.76 (-0.28%)
MSFT   287.13 (-0.70%)
META   177.45 (-0.50%)
GOOGL   118.99 (-0.59%)
AMZN   140.55 (-1.50%)
TSLA   858.99 (-2.73%)
NVDA   179.45 (-0.84%)
NIO   20.91 (+4.29%)
BABA   94.66 (+2.41%)
AMD   98.21 (-0.85%)
MU   62.41 (+1.64%)
T   18.06 (+0.28%)
CGC   3.16 (-3.95%)
GE   78.94 (+2.33%)
F   15.80 (+1.94%)
DIS   117.40 (+4.42%)
AMC   25.61 (+8.20%)
PYPL   99.05 (+0.14%)
PFE   48.26 (-3.38%)
NFLX   242.71 (-0.57%)
NYSE:BHVN

Biohaven Pharmaceutical - BHVN Stock Forecast, Price & News

$147.50
+0.39 (+0.27%)
(As of 08/11/2022 03:35 PM ET)
Add
Compare
Today's Range
$147.15
$147.67
50-Day Range
$143.71
$147.35
52-Week Range
$79.01
$151.51
Volume
9,421 shs
Average Volume
555,174 shs
Market Capitalization
$10.55 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$157.17

Biohaven Pharmaceutical MarketRank™ Forecast

Analyst Rating
Hold
2.29 Rating Score
Upside/​Downside
6.6% Upside
$157.17 Price Target
Short Interest
Healthy
8.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.02mentions of Biohaven Pharmaceutical in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($11.16) to ($7.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.32 out of 5 stars

Medical Sector

1074th out of 1,112 stocks

Pharmaceutical Preparations Industry

526th out of 544 stocks

BHVN stock logo

About Biohaven Pharmaceutical (NYSE:BHVN) Stock

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on BHVN. Cantor Fitzgerald cut shares of Biohaven Pharmaceutical from an "overweight" rating to a "neutral" rating in a research report on Wednesday, May 11th. SVB Leerink lowered Biohaven Pharmaceutical from an "outperform" rating to a "market perform" rating and set a $150.00 target price on the stock. in a research report on Wednesday, May 11th. Wedbush downgraded Biohaven Pharmaceutical from an "outperform" rating to a "neutral" rating and set a $148.50 price target for the company. in a report on Monday. HC Wainwright cut shares of Biohaven Pharmaceutical from a "buy" rating to a "neutral" rating in a report on Wednesday, May 11th. Finally, Piper Sandler lowered their target price on shares of Biohaven Pharmaceutical from $156.00 to $149.00 and set a "na" rating for the company in a report on Tuesday, May 24th. Six research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Biohaven Pharmaceutical presently has a consensus rating of "Hold" and a consensus target price of $157.17.

Biohaven Pharmaceutical Stock Down 0.2 %

NYSE:BHVN traded down $0.24 during trading hours on Wednesday, reaching $147.11. 648,322 shares of the company's stock were exchanged, compared to its average volume of 1,103,674. The firm has a market capitalization of $10.38 billion, a price-to-earnings ratio of -9.93 and a beta of 1.03. Biohaven Pharmaceutical has a 1-year low of $79.01 and a 1-year high of $151.51. The company has a 50-day moving average of $145.48 and a 200 day moving average of $130.61.

Biohaven Pharmaceutical (NYSE:BHVN - Get Rating) last released its quarterly earnings results on Tuesday, May 10th. The company reported ($2.97) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.52) by ($0.45). The company had revenue of $318.85 million during the quarter, compared to analysts' expectations of $187.12 million. During the same quarter in the prior year, the company posted ($4.21) earnings per share. Research analysts forecast that Biohaven Pharmaceutical will post -10.51 EPS for the current fiscal year.

Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BHVN Stock News Headlines

27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates BHVN, MANT, SWCH
See More Headlines
Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BHVN Company Calendar

Last Earnings
11/08/2021
Today
8/11/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Previous Symbol
NASDAQ:BHVN
Fax
N/A
Employees
928
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$157.17
High Stock Price Forecast
$177.00
Low Stock Price Forecast
$146.00
Forecasted Upside/Downside
+6.6%
Consensus Rating
Hold
Rating Score (0-4)
2.29
Research Coverage
7 Analysts

Profitability

Net Income
$-846,590,000.00
Net Margins
-108.04%
Pretax Margin
-105.78%

Debt

Sales & Book Value

Annual Sales
$462.51 million
Book Value
($11.27) per share

Miscellaneous

Free Float
62,630,000
Market Cap
$10.55 billion
Optionable
Optionable
Beta
1.03

Key Executives














BHVN Stock - Frequently Asked Questions

Should I buy or sell Biohaven Pharmaceutical stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BHVN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHVN, but not buy additional shares or sell existing shares.
View BHVN analyst ratings
or view top-rated stocks.

What is Biohaven Pharmaceutical's stock price forecast for 2022?

7 brokerages have issued 12-month price targets for Biohaven Pharmaceutical's stock. Their BHVN share price forecasts range from $146.00 to $177.00. On average, they expect the company's stock price to reach $157.17 in the next twelve months. This suggests a possible upside of 6.6% from the stock's current price.
View analysts price targets for BHVN
or view top-rated stocks among Wall Street analysts.

How have BHVN shares performed in 2022?

Biohaven Pharmaceutical's stock was trading at $137.81 at the beginning of the year. Since then, BHVN stock has increased by 7.0% and is now trading at $147.41.
View the best growth stocks for 2022 here
.

When is Biohaven Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our BHVN earnings forecast
.

How were Biohaven Pharmaceutical's earnings last quarter?

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) announced its quarterly earnings results on Monday, November, 8th. The company reported ($2.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by $0.23. The firm earned $135.74 million during the quarter, compared to analyst estimates of $128.40 million. The firm's revenue for the quarter was up 668.5% compared to the same quarter last year. During the same quarter last year, the business posted ($3.27) EPS.

What other stocks do shareholders of Biohaven Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

When did Biohaven Pharmaceutical IPO?

(BHVN) raised $124 million in an initial public offering on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

What is Biohaven Pharmaceutical's stock symbol?

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Who are Biohaven Pharmaceutical's major shareholders?

Biohaven Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (1.29%), JPMorgan Chase & Co. (1.23%), Brown Advisory Inc. (1.06%), Versor Investments LP (0.99%), Alpine Associates Management Inc. (0.76%) and UBS Group AG (0.38%). Insiders that own company stock include Declan Doogan, Elyse Stock, Eric Aguiar, George C Clark, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Robert Berman and William A Jones Jr.
View institutional ownership trends
.

How do I buy shares of Biohaven Pharmaceutical?

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biohaven Pharmaceutical's stock price today?

One share of BHVN stock can currently be purchased for approximately $147.41.

How much money does Biohaven Pharmaceutical make?

Biohaven Pharmaceutical (NYSE:BHVN) has a market capitalization of $10.54 billion and generates $462.51 million in revenue each year. The company earns $-846,590,000.00 in net income (profit) each year or ($14.82) on an earnings per share basis.

How many employees does Biohaven Pharmaceutical have?

The company employs 928 workers across the globe.

How can I contact Biohaven Pharmaceutical?

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The official website for the company is www.biohavenpharma.com. The company can be reached via phone at (203) 404-0410 or via email at jennifer.porcelli@biohavenpharma.com.

This page (NYSE:BHVN) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.